CLINICAL TRIALS PROFILE FOR RITALIN LA

All Clinical Trials for RITALIN LA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	National Institute of Mental Health (NIMH)	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	New York State Psychiatric Institute	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00025779 ↗	Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders	Completed	National Institute of Mental Health (NIMH)	N/A	2001-10-01	This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	Oregon Health and Science University	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	US Department of Veterans Affairs	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	VA Office of Research and Development	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00136734 ↗	Methylphenidate Treatment for Cocaine Abuse and ADHD - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 1	1998-04-01	Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.

Clinical Trial Conditions for RITALIN LA

Condition Name

Condition Name for RITALIN LA
Intervention	Trials
Attention Deficit Hyperactivity Disorder	26
Healthy	11
Attention Deficit Disorder With Hyperactivity	7
Fatigue	5

Condition MeSH

Condition MeSH for RITALIN LA
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	48
Hyperkinesis	35
Disease	24
Fatigue	9

Clinical Trial Locations for RITALIN LA

Trials by Country

Trials by Country for RITALIN LA
Location	Trials
United States	106
Israel	19
Canada	11
Netherlands	4
Switzerland	4

Trials by US State

Trials by US State for RITALIN LA
Location	Trials
California	13
Texas	10
Massachusetts	10
Maryland	9
Ohio	8

Clinical Trial Progress for RITALIN LA

Clinical Trial Phase

Clinical Trial Phase for RITALIN LA
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	37
Phase 3	14

Clinical Trial Status

Clinical Trial Status for RITALIN LA
Clinical Trial Phase	Trials
Completed	67
Unknown status	20
Terminated	13

Clinical Trial Sponsors for RITALIN LA

Sponsor Name

Sponsor Name for RITALIN LA
Sponsor	Trials
National Institute of Mental Health (NIMH)	8
Massachusetts General Hospital	8
M.D. Anderson Cancer Center	6

Sponsor Type

Sponsor Type for RITALIN LA
Sponsor	Trials
Other	165
NIH	23
Industry	16

RITALIN LA Market Analysis and Financial Projection

Last updated: April 27, 2026

Clinical Trials Update, Market Analysis, and Projection for Ritalin LA (methylphenidate hydrochloride extended-release)

What is Ritalin LA and how is it positioned clinically?

Ritalin LA is an extended-release formulation of methylphenidate hydrochloride indicated for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. It is designed for once-daily dosing using a bead-based extended-release technology. Product labeling places Ritalin LA within the standard stimulant class for ADHD care and aligns it with the therapeutic objective of improving core symptoms (inattention, hyperactivity-impulsivity) over the school day.

Key product characteristics (label-level positioning)

• Active ingredient: methylphenidate hydrochloride
• Formulation: extended-release (once daily)
• Indication: ADHD (6 years and older)
• Clinical role: first-line stimulant option; competitive against other extended-release methylphenidate products and long-acting amphetamine formulations depending on formulary and payer preference.
  Source: FDA prescribing information for Ritalin LA (methylphenidate HCl extended-release) [1].

What is the clinical trials landscape for Ritalin LA?

Ritalin LA is an established product and, as a result, the clinical evidence base is mature. Current trial activity for “Ritalin LA” as a unique branded formulation is typically limited versus ongoing research on next-generation delivery systems, pediatric ADHD endpoints under newer guidelines, and comparative effectiveness studies across ADHD medicines.

Trials that matter for decision-making are generally of three types:

1. Bioavailability and formulation equivalence (often to support regulatory filings for the extended-release design or generic alignment)
2. Comparative effectiveness or safety studies in real-world or pragmatic settings (class or class-adjacent)
3. Switch studies (patients moving between long-acting stimulants)

For practical market and lifecycle forecasting, the most decision-relevant near-term “clinical trials update” for Ritalin LA is not brand-changing efficacy innovation; it is incremental evidence that supports continuation in formularies and payer coverage, plus safety and tolerability documentation consistent with the broader methylphenidate class. The labeling itself already summarizes the controlled trial evidence supporting efficacy and safety for ADHD in the approved population range.
Source: FDA prescribing information for Ritalin LA [1].

What does the labeling evidence say about efficacy and safety?

Efficacy framework (label summary)

• Controlled clinical studies support that once-daily extended-release methylphenidate improves ADHD symptoms relative to placebo over the intended treatment window.
• Labeling includes guidance on dosing initiation and titration, with clinical assessment of response and tolerability.

Safety considerations (label-level constraints that drive use and payer risk) Stimulants carry class-consistent safety monitoring needs. Labeling emphasizes:

• Cardiovascular screening considerations (history of structural cardiac abnormalities, arrhythmias, and similar risk factors)
• Psychiatric monitoring (including exacerbation of pre-existing psychotic or manic symptoms)
• Growth and appetite considerations in pediatric use
• Blood pressure and heart rate monitoring Source: FDA prescribing information for Ritalin LA [1].

---

Market Analysis: Where does Ritalin LA sit in ADHD and stimulant markets?

How big is the ADHD stimulant market and where does methylphenidate fit?

The ADHD medication market is dominated by stimulants, with methylphenidate and amphetamine forming the primary therapeutic categories. Ritalin LA competes inside the extended-release segment where payer policy and formulary design strongly influence share.

Market structure (competitive set)

• Direct category competitors: other extended-release methylphenidate brands and long-acting methylphenidate generics.
• Cross-class competitors: extended-release amphetamine products.
• Switch-driven competition: prescriber and patient switching among long-acting stimulants based on coverage, duration of effect, side-effect profile, and perceived “workday” coverage.

Payer-driven dynamic Extended-release stimulant coverage is shaped by:

• Preferential formulary tiers (often generic-first)
• Step therapy in some managed care plans
• Prior authorization triggers for brand use when generic equivalents are available

Given that Ritalin LA is an older branded product with widespread generic availability for methylphenidate extended-release, the brand’s commercial position is typically constrained by pricing and formulary access relative to generic methylphenidate ER products.

---

Projection: Revenue and share outlook through the next planning cycle

What drives the near-term outlook for Ritalin LA?

Ritalin LA’s trajectory is primarily determined by:

1. Generic substitution pressure: methylphenidate ER generics cap brand pricing power and volume.
2. Formulary access cycles: brand coverage changes when PBM formularies update.
3. Utilization growth: ADHD prevalence and treatment rates support market growth, but not necessarily brand growth.
4. Migration across long-acting formats: patients and prescribers often switch among long-acting stimulants for tolerability and day-to-day symptom control.

Clinical and label continuity risk Because Ritalin LA is established, there is no “approval risk” from a new formulation or a new active ingredient. The main risk is commercial: payer access and share retention versus lower-cost generics.

Market projection logic (brand-level)

Brand-level revenue for an established extended-release methylphenidate product generally follows a pattern:

• Stable to declining volume in mature geographies where generics are entrenched
• Fluctuating revenue based on contract pricing, formulary tiering, and rebalance of prescribing patterns toward or away from specific long-acting delivery technologies

Because the request requires a clinical trials update, market analysis, and projection specifically for “Ritalin LA,” the highest-value projection inputs are patent and exclusivity timelines, payer coverage durability, and generic competitive intensity. However, those inputs are not provided in the prompt beyond the drug name.

Under this constraint set, a quantified forward revenue model cannot be generated without introducing unsupported numbers.

What can be concluded from the evidence base and market structure

• Ritalin LA is an established methylphenidate ER brand with ongoing clinical use supported by labeling.
• Future growth is more likely to be modest at the brand level and driven by incremental formulary access and prescribing behavior rather than by novel clinical differentiation.

Source for labeling and approved scope: FDA prescribing information for Ritalin LA [1].

---

Regulatory and lifecycle notes that affect projections

Is Ritalin LA still under meaningful exclusivity protection?

Ritalin LA contains methylphenidate hydrochloride, which is not protected by novel active-ingredient exclusivity in the modern sense; market competition is typically dominated by generic extended-release methylphenidate products. Brand viability depends on remaining brand-specific coverage, distribution contracts, and any formulation or marketing-related protections rather than on sustained active ingredient monopoly.

Source: FDA prescribing information for Ritalin LA [1].

---

Key Takeaways

• Ritalin LA is an established once-daily extended-release methylphenidate product for ADHD in patients aged 6+, with efficacy and safety supported by FDA labeling. [1]
• The clinical trials update for the brand is primarily mature-label continuation; current branded “new data” is not the main driver of market position.
• Market outlook is constrained by generic substitution and formulary design, meaning brand-level volume and revenue are more likely to be stable-to-declining unless contract coverage improves.
• Projections for Ritalin LA should be built on payer access scenarios and competitive switching rather than on new clinical breakthroughs.

---

FAQs

1) What is the approved indication for Ritalin LA?

Ritalin LA is approved for ADHD in patients aged 6 years and older. [1]

2) What drug class is Ritalin LA in?

It is a stimulant and a methylphenidate extended-release formulation. [1]

3) Does Ritalin LA change the safety profile versus other stimulants?

It shares class-consistent stimulant risks, and the label emphasizes cardiovascular and psychiatric monitoring considerations, plus pediatric growth and appetite monitoring. [1]

4) Are there likely many head-to-head brand-level trials for Ritalin LA today?

Branded formulation-level trials are generally less frequent for mature products; most ongoing evidence in practice centers on comparative effectiveness and formulation equivalence rather than new brand-defining efficacy. (Clinical evidence is captured in mature label documentation.) [1]

5) What is the key commercial factor shaping Ritalin LA projections?

Formulary access under generic competition (PBM tiering, prior authorization, and switch behavior among long-acting stimulants).

---

References

[1] U.S. Food and Drug Administration. Ritalin LA (methylphenidate hydrochloride) prescribing information. FDA label.